Concert Pharmaceuticals, Inc.
https://www.concertpharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Concert Pharmaceuticals, Inc.
Neurocrine Not Giving Up On Luvadaxistat Despite Phase II Miss
Schizophrenia drug licensed from Takeda missed Phase II endpoint for negative symptoms, but hits secondary cognition endpoints. Neurocrine plans to further study compound for cognitive benefits.
Keeping Track: The Breakthrough Designations Of Summer Eschew Phase I
The latest breakthrough therapy designation announcements from the Pink Sheet’s US FDA Performance Tracker
Tech Transfer Roundup: Hoth Teams With VCU On Therapy To Block COVID-19 Replication
Pandemic-related collaborations between Hoth/VCU; Sorrento/Mt. Sinai Health; Audax/Northeastern U.; Alkido/U. of Maryland, Baltimore; Active Motif/Hisun BioRay/Fudan U. and more.
Finance Watch: Billions Of Dollars In Offerings Despite US Biopharma Stock Slump
Blueprint and Zymeworks raise $300m-plus in follow-on offerings. Also, Arcutis, Black Diamond and Annovis bring the 2020 US IPO count to four; Spring Bank, Surface Oncology and Decibel reveal strategic shifts; and Harmony’s $200m in venture debt leads recent VC deals.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- ADMET
-
Molecular Diversity
- Natural Products
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- Concert Pharmaceuticals Inc.